恩华药业：获得药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration certificate of the chemical drug Ketorolac Tromethamine Injection, marking its first non-steroidal anti-inflammatory drug (NSAID) for perioperative injection, which enhances its product pipeline in the analgesic market and is expected to positively impact future performance [1] Group 1 - The approval of Ketorolac Tromethamine Injection enriches the company's product line in the pain relief medication sector [1] - This product is expected to improve the company's market competitiveness [1] - The launch and sales of this drug are anticipated to have a positive effect on the company's future performance [1]